Clinical Trials in San Francisco, CA
Here are the 6 most popular medical studies in san francisco
Normal Cognition (NC) with at least 1 vascular risk factor for Dementia
Recruiting1 award10 criteria
San Francisco, California
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID) is an NIH-funded consortium dedicated to finding biomarkers involved in age-related thinking and memory problems. Alzheimer's disease and other dementias leave signatures on brain scans or in the blood called biomarkers. The MarkVCID study will measure a panel of candidate biomarkers in 1800 participants and watch them closely to see what they tell us about changes in brain function and risk of memory loss. Age-related problems in thinking and memory represent some of the greatest risks to public health in the US and globally. Diseases that affect small blood vessels in the brain have been shown to be major contributors to these changes. However, research and patient care can be held back by limited biomarkers that identify who should be treated. The MarkVCID Consortium includes 17 US medical centers, a Coordinating Center, an External Advisory Committee, and NIH leadership. Data and biospecimens collected as part of this research study will be stored in a research database and biorepositories, so that researchers can use this information to study brain function.
Re-resection for Glioblastoma
Recruiting1 award4 criteria
San Francisco, California
Previous evidence has indicated that resection for recurrent glioblastoma might benefit the prognosis of these patients in terms of overall survival. However, the demonstrated safety profile of this approach is contradictory in the literature and the specific benefits in distinct clinical and molecular patient subgroups remains ill-defined. The aim of this study, therefore, is to compare the effects of resection and best oncological treatment for recurrent glioblastoma as a whole and in clinically important subgroups. This study is an international, multicenter, prospective observational cohort study. Recurrent glioblastoma patients will undergo tumor resection or best oncological treatment at a 1:1 ratio as decided by the tumor board. Primary endpoints are: 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks after surgery and 2) overall survival. Secondary endpoints are: 1) progression-free survival (PFS), 2) NIHSS deterioration at 3 months and 6 months after surgery, 3) health-related quality of life (HRQoL) at 6 weeks, 3 months, and 6 months after surgery, and 4) frequency and severity of Serious Adverse Events (SAEs) in each arm. Estimated total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year. The study has been approved by the Medical Ethics Committee (METC Zuid-West Holland/Erasmus Medical Center; MEC-2020-0812). The results will be published in peer-reviewed academic journals and disseminated to patient organisations and media.
Behavioural Intervention
SkillTalk for Autism Spectrum Disorder
Recruiting1 award
Santa Cruz, California
"This trial aims to see if a video training program can help young adults with autism spectrum disorder improve their communication and relationship skills. Participants will watch videos, take surveys, and participate in roleplay scenarios to
Behavioral Intervention
Mindfulness Program for Rheumatoid Arthritis
Recruiting1 award
San Francisco, California
This trial will test a mindfulness program in individuals with rheumatoid arthritis (RA). The goals are to assess patient satisfaction, identify barriers to participation, and understand how mindfulness impacts RA symptoms. Participants will
Awake mapping for Glioblastoma
Recruiting1 award5 criteria
San Francisco, California
Resection of glioblastoma in or near functional brain tissue is challenging because of the proximity of important structures to the tumor site. To pursue maximal resection in a safe manner, mapping methods have been developed to test for motor and language function during the operation. Previous evidence suggests that these techniques are beneficial for maximum safe resection in newly diagnosed grade 2-4 astrocytoma, grade 2-3 oligodendroglioma, and recently, glioblastoma. However, their effects in recurrent glioblastoma are still poorly understood. The aim of this study, therefore, is to compare the effects of awake mapping and asleep mapping with no mapping in resections for recurrent glioblastoma. This study is an international, multicenter, prospective 3-arm cohort study of observational nature. Recurrent glioblastoma patients will be operated with mapping or no mapping techniques with a 1:1 ratio. Primary endpoints are: 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks, 3 months, and 6 months after surgery and 2) residual tumor volume of the contrast-enhancing and non-contrast-enhancing part as assessed by a neuroradiologist on postoperative contrast MRI scans. Secondary endpoints are: 1) overall survival (OS), 2) progression-free survival (PFS), 4) health-related quality of life (HRQoL) at 6 weeks, 3 months, and 6 months after surgery, and 4) frequency and severity of Serious Adverse Events (SAEs) in each arm. Estimated total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year. The study will be carried out by the centers affiliated with the European and North American Consortium and Registry for Intraoperative Mapping (ENCRAM).
Insulin Delivery Device
SteadiSet Extended Wear Infusion Set for Type 1 Diabetes
Recruiting1 award
Stanford, California
This trial aims to gather data on wearing the Extended Wear Infusion Set for 7 days. Participants will wear the device for 12 periods and monitor their blood glucose and ketone levels if needed.
Popular filter options for san francisco trials
Phase 3 Clinical Trials
View 87 phase 3 medical studies.
Corticosteroid
Budesonide +1 More for Chronic Obstructive Pulmonary Disease
Recruiting2 awardsPhase 3
Sacramento, California
This trial will compare the effect of using a combination inhaler (BGF) containing three types of medication versus a different combination inhaler (GFF) in people with COPD and high risk for
Monoclonal Antibodies
Amlitelimab for Atopic Dermatitis
Recruiting1 awardPhase 3
Fremont, California
This trial is testing a new treatment for people with moderate-to-severe atopic dermatitis who have not responded well to other therapies. The study will compare the effectiveness and safety of the new treatment,
Procedure
Valeda Light Delivery System for Age-Related Macular Degeneration
Recruiting1 awardPhase 2 & 3
Palo Alto, California
This trial is a continuation of a previous study on the use of photobiomodulation in people with dry age-related macular degeneration. It is open to participants from multiple centers.
Clinical Trials With No Placebo
View 87 medical studies that do not have a placebo group.
Kinase Inhibitor
Avapritinib +1 More for Systemic Mastocytosis
Recruiting1 awardPhase 1
Palo Alto, California
"This trial aims to study a new treatment for a challenging disease called systemic mastocytosis with an associated hematologic neoplasm. Current treatments only target one aspect of the disease, leading to progression
Primary Anatomic for Shoulder Osteoarthritis
Recruiting1 award6 criteria
San Francisco, California
The goal of this study is to confirm the safety and performance of the AETOS Shoulder System for USA adoption. This is a prospective, open, adaptive, non-comparative, multi-centre investigation enrolling a maximum of 220 subjects in 2 cohorts (anatomic and reverse) at up to 15 sites. No intra-study comparator group will be included, and there will be no randomization
Procedure
Surgery +1 More for Idiopathic Toe Walking
Recruiting1 award
Sacramento, California
This trial aims to study the outcomes of treating children with idiopathic toe walking either without surgery (casting) or with surgery. The goal is to see which treatment option leads to better results in terms of
Layered Closure with Running Locking Suture on Side B for Scarring
Recruiting1 award
Sacramento, California
This trial compares two different ways to close wounds on the head and face after surgery. One way is the standard running sutures, where a single strand of suture is used along the length of the
View More San Francisco Trials
See another 69 medical studies focused on san francisco.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.